i-mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders. it is developing felzartamab (tj202), a cd38 antibody that is in phase iii clinical trials to treat multiple myeloma and autoimmune diseases; eftansomatropin (tj101), a long-acting human growth hormone that has completed phase ii clinical trials to treat pediatric growth hormone deficiency; and olamkicept (tj301), a il-6 blocker, which is in phase ii clinical trials for the treatment of ulcerative colitis and autoimmune diseases. the company's product candidates also include enoblituzumab, a humanized b7-h3 antibody that has completed phase i clinical trials to treat head and neck cancer and other oncology diseases; efineptakin (tj107), a long-acting recombinant human il-7, which is in phase 2 clinical trials to treat glioblastoma multiforme (gbm
Company profile
Ticker
IMAB
Exchange
Website
CEO
Hua Qiong Shen
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
IMAB stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
15 Apr 24
6-K
I-Mab Announces Closing of the Divestiture of Business Operations in China
2 Apr 24
6-K
Current report (foreign)
1 Apr 24
6-K
I-Mab Reports Full Year 2023 Financial Results and Business Update
15 Mar 24
6-K
I-Mab Signs Agreement
7 Feb 24
6-K
Current report (foreign)
6 Feb 24
6-K
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1BB Bispecific Antibody TJ-L14B/ABL503
10 Oct 23
6-K
Current report (foreign)
22 Sep 23
6-K
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
17 Aug 23
UPLOAD
Letter from SEC
14 Aug 23
Latest ownership filings
144
Notice of proposed sale of securities
15 Mar 24
SC 13G/A
GIC Private Ltd
13 Feb 24
SC 13G/A
Zang Jingwu Zhang
9 Feb 24
144
Notice of proposed sale of securities
8 Feb 24
144
Notice of proposed sale of securities
5 Jan 24
144
Notice of proposed sale of securities
29 Dec 23
144
Notice of proposed sale of securities
26 Dec 23
SC 13D
T Investment Ltd
1 Dec 23
144
Notice of proposed sale of securities
16 Nov 23
144
Notice of proposed sale of securities
10 Oct 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 55 |
Opened positions | 13 |
Closed positions | 12 |
Increased positions | 9 |
Reduced positions | 14 |
13F shares | Current |
---|---|
Total value | 32.69 bn |
Total shares | 156.19 mm |
Total puts | 12.70 k |
Total calls | 8.40 k |
Total put/call ratio | 1.5 |
Largest owners | Shares | Value |
---|---|---|
Fortune Eight Jogging | 83.02 mm | $0.00 |
CBC Investment I-Mab | 23.37 mm | $0.00 |
Tasly Biopharmaceuticals | 13.66 mm | $643.85 mm |
Genexine | 8.49 mm | $538.71 mm |
Hillhouse Capital Advisors | 6.91 mm | $9.12 bn |
Infini Master Fund | 5.00 mm | $0.00 |
Decheng Capital Management III | 4.17 mm | $13.31 bn |
Jingwu Zhang Zang | 3.24 mm | $0.00 |
MS Morgan Stanley | 988.68 k | $1.31 bn |
Artal | 850.00 k | $1.12 mm |
News
Needham Reiterates Buy on I-MAB, Maintains $6 Price Target
12 Apr 24
Piper Sandler Maintains Overweight on I-MAB, Lowers Price Target to $10
18 Mar 24
Needham Maintains Buy on I-MAB, Lowers Price Target to $6
15 Mar 24
I-Mab FY23 EPS $(0.76) Vs $(1.63) YoY; Revenue $3.9M Vs $(32.1M) YoY; FY23 EPADS $(1.76) Vs $(3.75) YoY
14 Mar 24
Needham Maintains Buy on I-MAB, Lowers Price Target to $8
8 Feb 24
Press releases
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
5 Apr 24
I-Mab to Participate at the 23rd Annual Needham Virtual Healthcare Conference
5 Apr 24
I-Mab Announces Closing of the Divestiture of Business Operations in China
2 Apr 24
I-Mab Reports Full Year 2023 Financial Results and Business Update
14 Mar 24
I-Mab Signs Agreement to Divest its Assets and Business Operations in China
7 Feb 24